Amobarbital

Lore & Background

Amobarbital was first synthesized in 1923 by Ernst Preiswerk in Switzerland and later manufactured by Eli Lilly in the United States as Amytal, available in blue bullet-shaped capsules (Pulvules) or pink tablets (Diskets) in 50, 100, or 200 milligram doses. It was also produced generically. The drug was widely misused, known on the street as 'Blue Heavens' or simply 'blues.' Eli Lilly also produced Tuinal, a combination of equal parts secobarbital and amobarbital, until the early 1990s (around 1991–1992).

Pharmacologically, amobarbital works by activating GABAA receptors, decreasing input resistance and depressing burst and tonic firing in certain thalamic neurons while increasing burst duration and chloride channel conductance. It has been studied for inhibiting mitochondrial electron transport in rat hearts and was found in a 1988 study to increase benzodiazepine receptor binding in vivo, with potency between secobarbital and phenobarbital.

Amobarbital gained notoriety for its use as a so-called truth serum when administered intravenously, first employed clinically by William Bleckwenn at the University of Wisconsin to circumvent inhibitions in psychiatric patients. This use has since lost credibility due to the risk of inducing false memories. The drug was also used by the United States Armed Forces during World War II to treat shell shock, but was discontinued because sedation and cognitive impairment reduced soldiers' effectiveness.

Reader's Guide

Amobarbital's significance lies in its role as a short to intermediate acting barbiturate that was widely prescribed for anxiety, epilepsy, and insomnia before being largely replaced by benzodiazepines in the mid to late 1980s. Its use in the Wada test—a procedure to lateralize language and memory function—remained an approved indication. The drug's reputation as a truth serum, though now discredited due to the potential for false memory creation, highlights its historical use in psychiatry and military medicine. Amobarbital's legacy also includes its association with notable deaths, such as actor Robert Walker in 1951 and comedian Tony Hancock in 1968, both involving combination with alcohol. The drug's withdrawal syndrome mimics delirium tremens and can be life-threatening, underscoring its potential for dependence. Its metabolism involves hydroxylation and N-glucosidation, and overdose can be fatal without intervention. The decline of amobarbital prescriptions reflects the broader shift in sedative-hypnotic prescribing from barbiturates to safer benzodiazepines.

Did You Know?

• It was known on the street as 'Blue Heavens' due to its blue capsules.
• Actor Robert Walker died in 1951 after a reaction between amobarbital and alcohol.

Origins, Production, and Decline

Amobarbital, a barbiturate derivative first synthesized in Germany in 1923, entered the pharmaceutical landscape as a white, odorless crystalline powder with a faintly bitter taste. In the United States, Eli Lilly and Company became its most prominent manufacturer, marketing it under the brand name Amytal in two distinctive forms: bright blue, bullet-shaped capsules called Pulvules and pink tablets called Diskets, each available in 50, 100, or 200 milligram strengths. The company also produced a generic version and a combination product called Tuinal, which paired equal parts of amobarbital with secobarbital. For decades, Amytal and Tuinal were staple prescriptions for sedation and sleep. However, the rise of the benzodiazepine class of drugs beginning in the mid-to-late 1980s steadily eroded demand for barbiturate-based sedatives. Prescriptions for these older agents became increasingly uncommon, and Eli Lilly ultimately discontinued production of both Amytal and Tuinal by the late 1990s, marking the end of an era in pharmacological sedation.

Pharmacological Profile and Metabolic Pathways

At the cellular level, amobarbital exerts its sedative-hypnotic effects primarily through the GABAA receptor system. In vitro research using rat thalamic tissue revealed that the drug reduces neuronal input resistance and suppresses both burst and tonic firing patterns, particularly in ventrobasal and intralaminar neurons. Simultaneously, it prolongs burst duration and elevates mean conductance at individual chloride channels, thereby amplifying the amplitude and extending the decay time of inhibitory postsynaptic currents. A 1988 in vivo study further established that amobarbital enhances benzodiazepine receptor binding, though with intermediate potency—ranking below secobarbital and pentobarbital but above phenobarbital and barbital. The compound's lethality in mice is quantified by an LD50 of 212 mg/kg when administered subcutaneously. In terms of metabolism, amobarbital is processed through two principal pathways: hydroxylation yielding 3'-hydroxyamobarbital, and N-glucosidation producing 1-(beta-D-glucopyranosyl)-amobarbital. Additionally, researchers have explored its capacity to inhibit mitochondrial electron transport in the rat heart as a potential strategy for preserving mitochondrial function after reperfusion injury.

Clinical Applications and Controversial Off-Label Uses

Amobarbital received formal approval for the treatment of anxiety, epilepsy, and insomnia, and it also found a specialized role in the Wada test, a neurological procedure. Beyond these sanctioned indications, the drug acquired a notorious reputation as a truth serum when administered slowly via intravenous injection. Under its influence, patients reportedly divulged information they would normally suppress, an effect attributed to a general loss of psychological inhibition. The earliest clinical deployment of this approach is credited to William Bleckwenn at the University of Wisconsin, who used it to bypass inhibitions in psychiatric patients. However, this practice has since lost scientific credibility because subjects can be coerced into fabricating false memories of events. In another clinical niche, intravenous amobarbital—sometimes combined with caffeine to counteract drowsiness—has been employed to elicit speech from patients suffering from catatonic mutism. Perhaps most dramatically, the United States Armed Forces turned to the drug during World War II to treat shell shock and rapidly return soldiers to front-line duties. This military application was abandoned after it became clear that the profound sedation, cognitive impairment, and motor dis-coordination the drug induced rendered soldiers far less effective in combat.

Cultural Footprint and Tragic Associations

The distinctive blue color of Amytal capsules gave rise to a constellation of street nicknames, including Blue Heavens, blues, blue angels, blue birds, and blue devils, reflecting the drug's widespread recreational misuse. Extended use of amobarbital carries a serious risk of both physical and psychological dependence, and withdrawal from the drug can mimic delirium tremens, a condition that may prove fatal without medical intervention. The substance's danger is underscored by two high-profile deaths in the entertainment world. On the night of August 28, 1951, actor Robert Walker was found in a distressed emotional state by his housekeeper; his psychiatrist administered amobarbital for sedation, and it is believed the combination of the drug with alcohol triggered a severe reaction that caused him to stop breathing. All resuscitation efforts failed, and Walker died at the age of 32. Decades later, in 1968, British actor and comedian Tony Hancock took his own life in Australia using amobarbital in combination with alcohol. These tragedies, alongside the drug's broad list of dangerous drug interactions and its potential to cause fatal respiratory depression in overdose, cement its legacy as a medication whose therapeutic benefits were ultimately overshadowed by its risks.